{"id":965,"date":"2021-04-29T08:42:39","date_gmt":"2021-04-29T08:42:39","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=965"},"modified":"2021-04-29T08:42:39","modified_gmt":"2021-04-29T08:42:39","slug":"10-apr-2021-itolizumab-was-found-to-be-safe-and-effective-immunomodulatory-therapy-for-the-treatment-of-crs","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/10-apr-2021-itolizumab-was-found-to-be-safe-and-effective-immunomodulatory-therapy-for-the-treatment-of-crs\/","title":{"rendered":"(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19<\/p>\n<p class=\"\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1905794<\/p>\n<p class=\"\">CTRI\/2020\/05\/024959- Patients were randomized (2:1) to Arm-A (best supportive care [BSC]+Itolizumab) and Arm-B (BSC). Primary outcome of interest was reduction in mortality 30-days after enrollment. Thirty-six patients were screened, five treated as first-dose-sentinels and rest randomized, while four patients were screen-failures. Two patients in Arm-A discontinued prior to receiving one complete infusion and were replaced. At end of 1-month, there were three deaths in Arm-B, and none in Arm-A (p = 0.0296; 95% CI = -0.3 [-0.61, -0.08]). At end of study, more patients in Arm-A had improved SpO2 without increasing FiO2 (p = 0.0296), improved PaO2 (p = 0.0296), and reduction in IL-6 (43 vs 212 pg\/ml; p = 0.0296) and tumor necrotic factor-alpha (9 vs 39 pg\/ml; p = 0.0253) levels. Transient lymphopenia (Arm-A: 11 patients) and infusion reactions (7 patients) were commonly reported treatment-related safety events. Itolizumab is a promising, safe and effective immunomodulatory therapy for treatment of ARDS due to cytokine release in COVID-19 patients, with survival and recovery-benefit.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1905794 CTRI\/2020\/05\/024959- Patients were randomized (2:1) to Arm-A (best supportive care [BSC]+Itolizumab) and Arm-B (BSC).&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/10-apr-2021-itolizumab-was-found-to-be-safe-and-effective-immunomodulatory-therapy-for-the-treatment-of-crs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,78],"tags":[79],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/965"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=965"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/965\/revisions"}],"predecessor-version":[{"id":966,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/965\/revisions\/966"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}